Skip to main content

Table 2 Comparison of costs (2020 AUD$) of resources used a

From: Evaluating the cost-effectiveness of [18F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients

 

FDG-PET/CT group (n = 65)

Standard CT group (n = 69)

Differences b

Mean

SD

Median

IQR

Mean

SD

Median

IQR

Mean

95% CI

Antimicrobialsc

673

906

438

308

504

285

418

225

168

-55

392

Diagnostic imagingd

1,008

91

953

94

832

852

811

1,152

176

-29

380

Invasive diagnostics

70

223

0

0

143

437

0

0

-73

-184

38

Pathology tests

233

285

164

303

335

382

217

386

-102

-213

8

CVC reinsertion

47

144

0

0

56

222

0

0

-9

-70

52

ICU

9,847

43,378

0

0

4,894

20,490

0

0

4,953

-6,632

16,539

Hospitalisation

39,507

34,759

29,314

26,383

47,795

45,800

35,177

23,452

-8,288

-21,737

5,160

Total cost

51,385

59,007

30,943

26,454

54,560

52,040

40,192

31,052

-3,175

-22,310

15,960

  1. a Not adjusted for baseline differences
  2. b 95% CI generated from 1000 replications using non-parametric bootstrap simulations
  3. c Related to treatment for febrile neutropenia episode
  4. d Includes cost of intervention FDG-PET/CT scan